KOSTAIVE® (ARCT-154)
COVID-19
ApprovedCommercial
Key Facts
About Arcturus Therapeutics
Arcturus Therapeutics is a fully integrated, commercial-stage biotech focused on developing mRNA medicines for infectious diseases and rare genetic disorders. Its key achievement is the global approval of KOSTAIVE®, the world's first authorized self-amplifying mRNA COVID-19 vaccine, validating its proprietary technology platforms. The company's strategy is to leverage its LUNAR® delivery and STARR™ saRNA platforms to build a diversified pipeline, advance wholly-owned rare disease programs, and expand through strategic partnerships for vaccines and therapeutics.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |
| UOL COVID-19 Test | Uh-Oh Labs | Approved |
| Lagevrio (molnupiravir) | Ridgeback Biotherapeutics | Approved/EUA |
| CVXGA | CyanVac | Phase 2 |